Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Research Reveals Insight into How Lung Cancer Spreads

2016-11-25
|
Page View:

        A cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center whose findings (“Epithelial-to-Mesenchymal Transition Drives a Pro-Metastatic Golgi Compaction Process through Scaffolding Protein PAQR11”) were reported in the Nov. 21 online issue of the Journal of Clinical Investigation.

   

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

   

   

        The Golgi apparatus, often referred to as a cellular “post office” for its ability to package proteins into vesicles for transportation to other sites within or outside the cell, may offer a new therapeutic approach for preventing metastasis. Think of vesicles as miniature mail trucks composed of a fatty shell filled with secretory liquids that travel from the Golgi to destinations within the cell where their contents are put to use, says Jonathan Kurie, M.D., professor of thoracic head and neck medical oncology. The Golgi can appear as a compacted membranous “stack” near the cell’s nucleus or as a dispersed system of interconnected membranes. Vesicles can “bud” from the Golgi in either form.

   

        “Our findings show that certain proteins in the Golgi that control Golgi compaction may actually promote vesicle budding and transport and enhance the tumor cell’s ability to metastasize,” notes Dr. Kurie. “These findings highlight the potential utility of targeting certain cellular processes in the Golgi.”

   

        According to Dr. Kurie, tumor cells gain their metastatic ability through a Golgi-related process driving the budding and transport of secretory vesicles. Unknown before this study was whether Golgi compaction was responsible for vesicular trafficking leading to metastasis. This study shows that Golgi compaction is associated with epithelial-to-mesenchymal transition (EMT), a process that allows a cell to detach and move away from its neighbors during wound healing and other normal processes and is thought to play a role in cancer cell migration.

   

Related Articles:

Analysis of the potential target of lung cancer treatment-aquaporin 4

[Nature] New treatment plan for non-small cell lung cancer: targeted degradation of EGFR

Lung Cancer Treatment Approach May Support Disease Progression

    Using lung adenocarcinoma cell lines isolated from mice and patients, Dr. Kurie’s team found that EMT depends on a Golgi protein called PAQR11 for successful tumor cell migration and metastasis in lung cancers. “We concluded that, through PAQR11, tumor cells can hijack a normal Golgi compaction process in order to gain metastatic ability,” he adds.

Return
Relevant newsRelevant news